Does increased experience with isolated limb infusion for advanced limb melanoma influence outcome? A comparison of two treatment periods at a single institution

Annals of Surgical Oncology

Volumn 18, Issue 7, 2011, Pages 1877-1883

  Huismans, Anna M ^a   Kroon, Hidde M ^a   Kam, Peter C A ^b,c   Thompson, John F ^a,b,c  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CREATINE KINASE; DACTINOMYCIN; MELPHALAN; PAPAVERINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ADVANCED LIMB MELANOMA; AGED; ARM; ARTICLE; BODY TEMPERATURE; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER INFILTRATION; CIRCULATION TIME; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATINE KINASE BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG METABOLISM; FASCIA; FEMALE; FOOT; FOREARM; HAND; HUMAN; ISOLATED LIMB INFUSION; LEG; LIMB DISEASE; LIMB PAIN; LIMB TEMPERATURE; LIMB TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOME ASSESSMENT; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PERIOD; SIDE EFFECT; SKIN; SKIN TEMPERATURE; SUBCUTANEOUS TISSUE; SYSTEMIC LEAKAGE; SYSTEMIC THERAPY; SYSTEMIC TOXICITY; THIGH; TREATMENT RESPONSE; TUMOR VOLUME; WIEBERDINK TOXICITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DACTINOMYCIN; EXTREMITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 80051550483     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1646-y     Document Type: Article

References (34)

1. Vrouenraets BC, Nieweg OE, Kroon BB. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg. 1996;83(10):1319-28. (Pubitemid 26342147)
2. Creech O, Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148(4):616-32.
3. Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BB. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol. 1998;14(3):224-31. (Pubitemid 28146514)
4. Thompson JF, de Wilt JH. Isolated limb perfusion in the management of patients with recurrent limb melanoma: an important but limited role. Ann Surg Oncol. 2001;8(7):564-5. (Pubitemid 32735035)
5. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14(3):238-47. (Pubitemid 28146516)
6. Thompson JF, Waugh RC, Saw RPM, Kam PCA. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat. 1994;7:188-92.
7. Thompson JF, Waugh RC, Kam PCA. "Stop-flow" cytotoxic infusion-a simplified technique using percutaneous catheters. Reg Cancer Treat. 1993;6(Supll 1):51. Presented to 4th International Conference on Regional Cancer Treatment, Wiesbaden, Germany, July 1993.
8. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008;15(11):3003-13.
9. Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg. 2009;208(5):706-15.
10. Mian R, Henderson MA, Speakman D, Finkelde D, Ainslie J, McKenzie A. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg. 2001;44(3):189-92. (Pubitemid 32538770)
11. Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol. 2002;9(2):127-36. (Pubitemid 34259697)
12. Lindner P, Thompson JF, De Wilt JH, ColmanM, Kam PC. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol. 2004;30(4):433-9. (Pubitemid 38528929)
13. Klaase JM, Kroon BB, van Geel AN, et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg. 1994;178(6):564-72. (Pubitemid 24172563)
14. Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. 1997;132(8):903-7. (Pubitemid 27344144)
15. Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg. 2007;245(4):591-6. (Pubitemid 46555663)
16. Kroon BB. Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future. Eur J Surg Oncol. 1988;14(2):101-10.
17. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18(10):905-10. (Pubitemid 13147887)
18. Lai DT, Ingvar C, Thompson JF. The value of monitoring serum creatine phosphokinase values following hyperthermic isolated limb perfusion for melanoma. Reg Cancer Treat. 1993;6:36-9. (Pubitemid 23287902)
19. Kroon HM, Moncrieff M, Kam PC, Thompson JF. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol. 2009;16(5):1184-92.
20. World Health Organization, editors. WHO handbook for reporting results of cancer treatments. Geneva: World Health Organization; 1979.
21. Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat. 1947;18:50-60.
22. Kaplan L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1985;53:457-81.
23. Skarsgard LD, Skwarchuk MW, Vinczan A, Kristl J, Chaplin DJ. The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res. 1995;15(1):219-23.
24. de Wilt JH, Manusama ER, van Tiel ST, van Ijken MG, ten Hagen TL, Eggermont AM. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer. 1999;80(1-2):161-6. (Pubitemid 29210102)
25. Siemann DW, Chapman M, Beikirch A. Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy. Int J Radiat Oncol Biol Phys. 1991;20(2):287-9.
26. Chaplin DJ, Acker B, Olive PL. Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs. Int J Radiat Oncol Biol Phys. 1989;16(5):1131-5. (Pubitemid 19137197)
27. Thompson JF, Ramzan I, Kam PCA, Yau DF. Pharmacokinetics of melphalan during isolated limb infusion for melanoma. Reg Cancer Treat. 1996;9:13-6. (Pubitemid 26360195)
28. Roberts MS, Wu ZY, Siebert GA, Anissimov YG, Thompson JF, Smithers BM. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res. 2001;11(4):423-31. (Pubitemid 32735234)
29. Klaase JM, Kroon BB, Beijnen JH, van Slooten GW, van Dongen JA. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer. 1994;70(1):151-3. (Pubitemid 24203644)
30. Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15(8):2195-205.
31. McMahon N, Cheng TY, Beasley GM, et al. Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol. 2009;16(4):953-61.
32. Kroon HM, Thompson JF. Isolated limb infusion: a review. J Surg Oncol. 2009;100(2):169-77.
33. Vrouenraets BC, Kroon BB, Klaase JM, et al. Value of laboratory tests in monitoring acute regional toxicity after isolated limb perfusion. Ann Surg Oncol. 1997;4(1):88-94. (Pubitemid 127727876)
34. Santillan AA, Delman KA, Beasley GM, et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol. 2009;16(9):2570-8.